FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy

ABSTRACT This is the first case report of Candida glabrata-disseminated candidiasis describing the acquisition of echinocandin resistance following anidulafungin treatment. The initial isolates recovered were susceptible to echinocandins. However, during 27 days of anidulafungin treatment, two resistant strains were isolated (from the blood and peritoneal fluid). The resistant peritoneal fluid isolate exhibited a Ser663Pro mutation in position 1987 of FKS2 HS1 (hot spot 1), whereas the resistant blood isolate displayed a phenylalanine deletion (Phe659).

[1]  M. Ghannoum,et al.  Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species , 2010, Antimicrobial Agents and Chemotherapy.

[2]  Ronald N. Jones,et al.  Low Prevalence of fks1 Hot Spot 1 Mutations in a Worldwide Collection of Candida Strains , 2010, Antimicrobial Agents and Chemotherapy.

[3]  J. Cleary,et al.  Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.

[4]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  T. Patterson,et al.  Development of Caspofungin Resistance following Prolonged Therapy for Invasive Candidiasis Secondary to Candida glabrata Infection , 2008, Antimicrobial Agents and Chemotherapy.

[6]  D. Kontoyiannis,et al.  The changing epidemiology of invasive candidiasis , 2008, Cancer.

[7]  S. Katiyar,et al.  A Naturally Occurring Proline-to-Alanine Amino Acid Change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis Accounts for Reduced Echinocandin Susceptibility , 2008, Antimicrobial Agents and Chemotherapy.

[8]  N. Gow,et al.  Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.

[9]  S. Costa-de-Oliveira,et al.  A first Portuguese epidemiological survey of fungaemia in a university hospital , 2008, European Journal of Clinical Microbiology & Infectious Diseases.

[10]  P. D. Rogers,et al.  Increases in SLT2 Expression and Chitin Content Are Associated with Incomplete Killing of Candida glabrata by Caspofungin , 2007, Antimicrobial Agents and Chemotherapy.

[11]  D. Perlin.  Resistance to echinocandin-class antifungal drugs. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  D. Stevens,et al.  Escape of Candida from Caspofungin Inhibition at Concentrations above the MIC (Paradoxical Effect) Accomplished by Increased Cell Wall Chitin; Evidence for β-1,6-Glucan Synthesis Inhibition by Caspofungin , 2006, Antimicrobial Agents and Chemotherapy.

[13]  S. Katiyar,et al.  Candida albicans and Candida glabrata Clinical Isolates Exhibiting Reduced Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.

[14]  Sergey V. Balashov,et al.  Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.

[15]  M. Arendrup,et al.  Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  D. Perlin,et al.  Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. , 2006, The Journal of antimicrobial chemotherapy.

[17]  M. Pfaller,et al.  Effectiveness of Anidulafungin in Eradicating Candida Species in Invasive Candidiasis , 2005, Antimicrobial Agents and Chemotherapy.

[18]  M. Motyl,et al.  Caspofungin Susceptibility Testing of Isolates from Patients with Esophageal Candidiasis or Invasive Candidiasis: Relationship of MIC to Treatment Outcome , 2005, Antimicrobial Agents and Chemotherapy.

[19]  S. A. Parent,et al.  Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[20]  Steve A. Hernandez,et al.  Caspofungin Resistance in Candida albicans: Correlating Clinical Outcome with Laboratory Susceptibility Testing of Three Isogenic Isolates Serially Obtained from a Patient with Progressive Candida Esophagitis , 2004, Antimicrobial Agents and Chemotherapy.

[21]  N. Wiederhold,et al.  The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy , 2003, Expert opinion on investigational drugs.

[22]  L. Villa-Tanaca,et al.  Identification of Candida spp. by Randomly Amplified Polymorphic DNA Analysis and Differentiation between Candida albicans and Candida dubliniensis by Direct PCR Methods , 2003, Journal of Clinical Microbiology.

[23]  J. Rex,et al.  Has antifungal susceptibility testing come of age? , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  M. Pfaller,et al.  Role of Sentinel Surveillance of Candidemia: Trends in Species Distribution and Antifungal Susceptibility , 2002, Journal of Clinical Microbiology.

[25]  Steven D. Brown,et al.  Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .

[26]  Ortwin Renn,et al.  SIXTH FRAMEWORK PROGRAMME , 2007 .

[27]  P. Wayne.  Reference method for broth dilution antifungal susceptibility testing of yeasts, Approved standard-second edition , 2002 .